Despite conflicting views regarding the role of HDACs in treating PH, recent research has shown that developing more selective HDAC inhibitors that target specific isoforms can lead to effective and targeted therapies for PAH and related vascular remodeling diseases. The gene discussed is HDAC9; the disease is pulmonary arterial hypertension.